Valneva : H1 impacted by COVID-19, guidance for 2020 revised up
>H1 severely impacted by the COVID-19 crisis - This morning, Valneva published its H1 results which reveal, as anticipated, a marked impact from COVID-19. Sales were € 47.9m over the period (vs € 51.6m est.). As Sanofi reported several days ago, sales of the traveller’s vaccine slowed significantly over the period. Ixiaro generated sales of just € 28.4m for the H1 2020 period vs € 30.2m forecast, down 38% l-f-l. The new bid tenders with the US Department of Defence ha...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.